HC Wainwright Begins Coverage on Tyme Technologies (TYME)
HC Wainwright began coverage on shares of Tyme Technologies (NASDAQ:TYME) in a report released on Friday, MarketBeat.com reports. The firm issued a buy rating and a $8.00 target price on the stock.
Separately, Evercore ISI began coverage on Tyme Technologies in a research note on Friday, November 17th. They issued an outperform rating and a $7.00 price objective for the company.
Shares of Tyme Technologies (TYME) opened at $3.64 on Friday. Tyme Technologies has a 12 month low of $1.01 and a 12 month high of $9.50.
WARNING: “HC Wainwright Begins Coverage on Tyme Technologies (TYME)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/hc-wainwright-begins-coverage-on-tyme-technologies-tyme/1770541.html.
Tyme Technologies Company Profile
Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.